{"publication_id":"f1b39b71-2cc3-43a3-ab5a-287574699c7d","traces":[{"claim_id":"claim_1","claim":"This paper synthesizes evidence on Statin across 62 accepted source papers and 1367 high-confidence extracted claims. The evidence profile contains 4 direct clinical sources, 58 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence, with a high-density pairwise disagreement map across the evidence base. Positive study-level signals are summarized in the contextual adjacent evidence, longevity and cardiometabolic outcome classes, null signals in the contextual adjacent evidence, cardiometabolic, dosing and pharmacokinetics outcome classes, and negative signals in no dominant outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that Statin remains a bounded evidence case: the retained direct, adjacent, and context evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified broad clinical claim. For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.","citation_support":[],"candidate_sources":[{"study":"Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer","year":2023,"doi":"10.1186/s12885-023-10631-w","url":"https://doi.org/10.1186/s12885-023-10631-w","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials","year":2024,"doi":"10.1016/j.athplu.2024.10.001","url":"https://doi.org/10.1016/j.athplu.2024.10.001","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation","year":2026,"doi":"10.1016/j.eclinm.2026.103798","url":"https://doi.org/10.1016/j.eclinm.2026.103798","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin","year":2020,"doi":"10.12997/jla.2020.9.2.283","url":"https://doi.org/10.12997/jla.2020.9.2.283","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer’s patients: A double-blind placebo-controlled randomized clinical trial","year":2024,"doi":"10.1016/j.ibneur.2024.07.002","url":"https://doi.org/10.1016/j.ibneur.2024.07.002","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_2","claim":"This paper synthesizes evidence on Statin across 62 accepted source papers and 1367 high-confidence extracted claims.","citation_support":[],"candidate_sources":[{"study":"Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer","year":2023,"doi":"10.1186/s12885-023-10631-w","url":"https://doi.org/10.1186/s12885-023-10631-w","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials","year":2024,"doi":"10.1016/j.athplu.2024.10.001","url":"https://doi.org/10.1016/j.athplu.2024.10.001","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation","year":2026,"doi":"10.1016/j.eclinm.2026.103798","url":"https://doi.org/10.1016/j.eclinm.2026.103798","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin","year":2020,"doi":"10.12997/jla.2020.9.2.283","url":"https://doi.org/10.12997/jla.2020.9.2.283","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer’s patients: A double-blind placebo-controlled randomized clinical trial","year":2024,"doi":"10.1016/j.ibneur.2024.07.002","url":"https://doi.org/10.1016/j.ibneur.2024.07.002","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_3","claim":"The evidence profile contains 4 direct clinical sources, 58 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence, with a high-density pairwise disagreement map across the evidence base.","citation_support":[],"candidate_sources":[{"study":"Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer","year":2023,"doi":"10.1186/s12885-023-10631-w","url":"https://doi.org/10.1186/s12885-023-10631-w","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials","year":2024,"doi":"10.1016/j.athplu.2024.10.001","url":"https://doi.org/10.1016/j.athplu.2024.10.001","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation","year":2026,"doi":"10.1016/j.eclinm.2026.103798","url":"https://doi.org/10.1016/j.eclinm.2026.103798","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin","year":2020,"doi":"10.12997/jla.2020.9.2.283","url":"https://doi.org/10.12997/jla.2020.9.2.283","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer’s patients: A double-blind placebo-controlled randomized clinical trial","year":2024,"doi":"10.1016/j.ibneur.2024.07.002","url":"https://doi.org/10.1016/j.ibneur.2024.07.002","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_4","claim":"Positive study-level signals are summarized in the contextual adjacent evidence, longevity and cardiometabolic outcome classes, null signals in the contextual adjacent evidence, cardiometabolic, dosing and pharmacokinetics outcome classes, and negative signals in no dominant outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.","citation_support":[],"candidate_sources":[{"study":"Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer","year":2023,"doi":"10.1186/s12885-023-10631-w","url":"https://doi.org/10.1186/s12885-023-10631-w","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials","year":2024,"doi":"10.1016/j.athplu.2024.10.001","url":"https://doi.org/10.1016/j.athplu.2024.10.001","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation","year":2026,"doi":"10.1016/j.eclinm.2026.103798","url":"https://doi.org/10.1016/j.eclinm.2026.103798","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin","year":2020,"doi":"10.12997/jla.2020.9.2.283","url":"https://doi.org/10.12997/jla.2020.9.2.283","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer’s patients: A double-blind placebo-controlled randomized clinical trial","year":2024,"doi":"10.1016/j.ibneur.2024.07.002","url":"https://doi.org/10.1016/j.ibneur.2024.07.002","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_5","claim":"The conclusion is that Statin remains a bounded evidence case: the retained direct, adjacent, and context evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified broad clinical claim.","citation_support":[],"candidate_sources":[{"study":"Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer","year":2023,"doi":"10.1186/s12885-023-10631-w","url":"https://doi.org/10.1186/s12885-023-10631-w","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials","year":2024,"doi":"10.1016/j.athplu.2024.10.001","url":"https://doi.org/10.1016/j.athplu.2024.10.001","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation","year":2026,"doi":"10.1016/j.eclinm.2026.103798","url":"https://doi.org/10.1016/j.eclinm.2026.103798","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin","year":2020,"doi":"10.12997/jla.2020.9.2.283","url":"https://doi.org/10.12997/jla.2020.9.2.283","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer’s patients: A double-blind placebo-controlled randomized clinical trial","year":2024,"doi":"10.1016/j.ibneur.2024.07.002","url":"https://doi.org/10.1016/j.ibneur.2024.07.002","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_6","claim":"For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.","citation_support":[],"candidate_sources":[{"study":"Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer","year":2023,"doi":"10.1186/s12885-023-10631-w","url":"https://doi.org/10.1186/s12885-023-10631-w","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials","year":2024,"doi":"10.1016/j.athplu.2024.10.001","url":"https://doi.org/10.1016/j.athplu.2024.10.001","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation","year":2026,"doi":"10.1016/j.eclinm.2026.103798","url":"https://doi.org/10.1016/j.eclinm.2026.103798","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin","year":2020,"doi":"10.12997/jla.2020.9.2.283","url":"https://doi.org/10.12997/jla.2020.9.2.283","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer’s patients: A double-blind placebo-controlled randomized clinical trial","year":2024,"doi":"10.1016/j.ibneur.2024.07.002","url":"https://doi.org/10.1016/j.ibneur.2024.07.002","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_7","claim":"For Statin, what does the retained evidence show about prognostic or risk-marker associations, causal or mechanistic evidence, treatment or intervention relevance across treatment or intervention-response evidence, adjacent clinical-context evidence, biology-mechanism and molecular-context evidence, and are those outcome-class source-level signals directionally consistent enough for clinical actionability once unclear direction coding, adjacent/contextual source roles, and directness limits are considered?","citation_support":[],"candidate_sources":[{"study":"Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer","year":2023,"doi":"10.1186/s12885-023-10631-w","url":"https://doi.org/10.1186/s12885-023-10631-w","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials","year":2024,"doi":"10.1016/j.athplu.2024.10.001","url":"https://doi.org/10.1016/j.athplu.2024.10.001","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation","year":2026,"doi":"10.1016/j.eclinm.2026.103798","url":"https://doi.org/10.1016/j.eclinm.2026.103798","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin","year":2020,"doi":"10.12997/jla.2020.9.2.283","url":"https://doi.org/10.12997/jla.2020.9.2.283","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer’s patients: A double-blind placebo-controlled randomized clinical trial","year":2024,"doi":"10.1016/j.ibneur.2024.07.002","url":"https://doi.org/10.1016/j.ibneur.2024.07.002","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_8","claim":"Several unresolved questions thread through this evidence base and are not adequately settled by any single trial or by the corpus taken as a whole. First, the translation from mechanistic biomarker shifts to functional aging outcomes remains uncertain, and the surrogate endpoint caution that Ioannidis 2005 raises applies with particular force when short-term biochemical changes are extrapolated to long-horizon endpoints such as lifespan. Second, the tradeoffs are not symmetric across populations: in Lee 2023 dialysis patients and in Guo 2019 patients aged 80 and over, safety and adherence profiles diverge from the cardiovascular prevention populations in which statins were initially validated. Third, dose-response, duration, and population specificity, including genotype interactions noted in Asiimwe 2024a and Asiimwe 2024b, all appear to moderate any signal, suggesting that the question of whether statins can extend healthspan may not have a single answer.","citation_support":[],"candidate_sources":[{"study":"Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer","year":2023,"doi":"10.1186/s12885-023-10631-w","url":"https://doi.org/10.1186/s12885-023-10631-w","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials","year":2024,"doi":"10.1016/j.athplu.2024.10.001","url":"https://doi.org/10.1016/j.athplu.2024.10.001","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation","year":2026,"doi":"10.1016/j.eclinm.2026.103798","url":"https://doi.org/10.1016/j.eclinm.2026.103798","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin","year":2020,"doi":"10.12997/jla.2020.9.2.283","url":"https://doi.org/10.12997/jla.2020.9.2.283","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer’s patients: A double-blind placebo-controlled randomized clinical trial","year":2024,"doi":"10.1016/j.ibneur.2024.07.002","url":"https://doi.org/10.1016/j.ibneur.2024.07.002","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_9","claim":"Against this background, the present synthesis deliberately separates clinical from mechanistic inference, treats surrogate endpoint patterns as hypothesis-generating rather than confirmatory in line with the cautionary framing of Ioannidis 2005, and organizes evidence by outcome class rather than by chronology. By weighting direct randomized designs separately from observational and review-class sources, and by surfacing the within-class tensions and cross-domain contradictions that the retained corpus exposes, the analysis aims to define the boundary conditions under which the statins aging case currently holds, and to clarify which gaps an aging-focused trial would need to close. The retained statins corpus supports translation only conditionally, and the question of broader healthspan or lifespan benefit appears to remain open rather than answered.","citation_support":[],"candidate_sources":[{"study":"Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer","year":2023,"doi":"10.1186/s12885-023-10631-w","url":"https://doi.org/10.1186/s12885-023-10631-w","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials","year":2024,"doi":"10.1016/j.athplu.2024.10.001","url":"https://doi.org/10.1016/j.athplu.2024.10.001","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation","year":2026,"doi":"10.1016/j.eclinm.2026.103798","url":"https://doi.org/10.1016/j.eclinm.2026.103798","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin","year":2020,"doi":"10.12997/jla.2020.9.2.283","url":"https://doi.org/10.12997/jla.2020.9.2.283","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer’s patients: A double-blind placebo-controlled randomized clinical trial","year":2024,"doi":"10.1016/j.ibneur.2024.07.002","url":"https://doi.org/10.1016/j.ibneur.2024.07.002","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_10","claim":"The geroscience hypothesis holds that interventions targeting the molecular hallmarks of aging — mitochondrial dysfunction, cellular senescence, dysregulated nutrient sensing, and altered proteostasis — could compress multimorbidity in later life rather than treating each disease in isolation. Within this framework, statins are an attractive candidate because their primary pharmacological target, HMG-CoA reductase inhibition, intersects several hallmark pathways beyond low-density lipoprotein cholesterol (LDL-C) lowering, including mevalonate-derived isoprenoid signalling, mitochondrial respiratory chain assembly, and NLRP3 inflammasome priming. Regulatory bodies have so far authorised statins almost exclusively for lipid-driven cardiovascular risk reduction, leaving their broader geroscience indications — cognitive preservation, frailty attenuation, and mortality in non-cardiovascular populations — outside formal approval pathways. The implication is that any aging-related use case for statins has to be argued from off-label evidence streams and is therefore inherently indirect. This synthesis examines what the curated corpus contributes to that argument, deliberately separating directly tested RCT endpoints from observational signals that may be hypothesis-generating only.","citation_support":[],"candidate_sources":[{"study":"Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer","year":2023,"doi":"10.1186/s12885-023-10631-w","url":"https://doi.org/10.1186/s12885-023-10631-w","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials","year":2024,"doi":"10.1016/j.athplu.2024.10.001","url":"https://doi.org/10.1016/j.athplu.2024.10.001","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation","year":2026,"doi":"10.1016/j.eclinm.2026.103798","url":"https://doi.org/10.1016/j.eclinm.2026.103798","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin","year":2020,"doi":"10.12997/jla.2020.9.2.283","url":"https://doi.org/10.12997/jla.2020.9.2.283","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer’s patients: A double-blind placebo-controlled randomized clinical trial","year":2024,"doi":"10.1016/j.ibneur.2024.07.002","url":"https://doi.org/10.1016/j.ibneur.2024.07.002","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_11","claim":"Five methodological problems recur across the retained evidence and constrain any claim of broad aging benefit. First, surrogate-endpoint reliance is heavy: surrogate endpoints are known not to guarantee hard-outcome validity (Ioannidis 2005), and biomarker-level drops in amyloid carriers or lipid intermediates may not translate to clinical events. Second, population heterogeneity is large — older adults, dialysis patients, HIV-positive cohorts, cancer patients, and post-COVID-19 cohorts — and pooling across them obscures indication-specific effects. Third, treatment duration rarely matches the latency implied by an aging endpoint; even the 6-month Rustamzadeh 2024 protocol is short relative to dementia pathogenesis. The synthesis therefore keeps outcome-class distinctions explicit: review-class evidence should be treated as hypothesis-generating only, and direct RCT evidence remains the only basis on which substantive claims about statins in aging populations can rest.","citation_support":[],"candidate_sources":[{"study":"Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer","year":2023,"doi":"10.1186/s12885-023-10631-w","url":"https://doi.org/10.1186/s12885-023-10631-w","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials","year":2024,"doi":"10.1016/j.athplu.2024.10.001","url":"https://doi.org/10.1016/j.athplu.2024.10.001","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation","year":2026,"doi":"10.1016/j.eclinm.2026.103798","url":"https://doi.org/10.1016/j.eclinm.2026.103798","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin","year":2020,"doi":"10.12997/jla.2020.9.2.283","url":"https://doi.org/10.12997/jla.2020.9.2.283","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer’s patients: A double-blind placebo-controlled randomized clinical trial","year":2024,"doi":"10.1016/j.ibneur.2024.07.002","url":"https://doi.org/10.1016/j.ibneur.2024.07.002","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_12","claim":"The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.","citation_support":[],"candidate_sources":[{"study":"Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer","year":2023,"doi":"10.1186/s12885-023-10631-w","url":"https://doi.org/10.1186/s12885-023-10631-w","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials","year":2024,"doi":"10.1016/j.athplu.2024.10.001","url":"https://doi.org/10.1016/j.athplu.2024.10.001","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation","year":2026,"doi":"10.1016/j.eclinm.2026.103798","url":"https://doi.org/10.1016/j.eclinm.2026.103798","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin","year":2020,"doi":"10.12997/jla.2020.9.2.283","url":"https://doi.org/10.12997/jla.2020.9.2.283","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer’s patients: A double-blind placebo-controlled randomized clinical trial","year":2024,"doi":"10.1016/j.ibneur.2024.07.002","url":"https://doi.org/10.1016/j.ibneur.2024.07.002","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_13","claim":"A source was coded as direct only when it tested the topic itself against a clinically proximate outcome in the relevant population. Human evidence with an adjacent exposure, population, or outcome was coded as indirect; syntheses and secondary reviews were coded as review-level evidence and were not counted as direct sources.","citation_support":[],"candidate_sources":[{"study":"Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer","year":2023,"doi":"10.1186/s12885-023-10631-w","url":"https://doi.org/10.1186/s12885-023-10631-w","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials","year":2024,"doi":"10.1016/j.athplu.2024.10.001","url":"https://doi.org/10.1016/j.athplu.2024.10.001","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation","year":2026,"doi":"10.1016/j.eclinm.2026.103798","url":"https://doi.org/10.1016/j.eclinm.2026.103798","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin","year":2020,"doi":"10.12997/jla.2020.9.2.283","url":"https://doi.org/10.12997/jla.2020.9.2.283","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer’s patients: A double-blind placebo-controlled randomized clinical trial","year":2024,"doi":"10.1016/j.ibneur.2024.07.002","url":"https://doi.org/10.1016/j.ibneur.2024.07.002","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_14","claim":"Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.","citation_support":[],"candidate_sources":[{"study":"Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer","year":2023,"doi":"10.1186/s12885-023-10631-w","url":"https://doi.org/10.1186/s12885-023-10631-w","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials","year":2024,"doi":"10.1016/j.athplu.2024.10.001","url":"https://doi.org/10.1016/j.athplu.2024.10.001","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation","year":2026,"doi":"10.1016/j.eclinm.2026.103798","url":"https://doi.org/10.1016/j.eclinm.2026.103798","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin","year":2020,"doi":"10.12997/jla.2020.9.2.283","url":"https://doi.org/10.12997/jla.2020.9.2.283","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer’s patients: A double-blind placebo-controlled randomized clinical trial","year":2024,"doi":"10.1016/j.ibneur.2024.07.002","url":"https://doi.org/10.1016/j.ibneur.2024.07.002","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_15","claim":"Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, dosing and pharmacokinetics, immune and inflammation, longevity, mortality and survival, muscle function, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.","citation_support":[],"candidate_sources":[{"study":"Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer","year":2023,"doi":"10.1186/s12885-023-10631-w","url":"https://doi.org/10.1186/s12885-023-10631-w","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials","year":2024,"doi":"10.1016/j.athplu.2024.10.001","url":"https://doi.org/10.1016/j.athplu.2024.10.001","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation","year":2026,"doi":"10.1016/j.eclinm.2026.103798","url":"https://doi.org/10.1016/j.eclinm.2026.103798","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin","year":2020,"doi":"10.12997/jla.2020.9.2.283","url":"https://doi.org/10.12997/jla.2020.9.2.283","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer’s patients: A double-blind placebo-controlled randomized clinical trial","year":2024,"doi":"10.1016/j.ibneur.2024.07.002","url":"https://doi.org/10.1016/j.ibneur.2024.07.002","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_16","claim":"Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.","citation_support":[],"candidate_sources":[{"study":"Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer","year":2023,"doi":"10.1186/s12885-023-10631-w","url":"https://doi.org/10.1186/s12885-023-10631-w","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials","year":2024,"doi":"10.1016/j.athplu.2024.10.001","url":"https://doi.org/10.1016/j.athplu.2024.10.001","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation","year":2026,"doi":"10.1016/j.eclinm.2026.103798","url":"https://doi.org/10.1016/j.eclinm.2026.103798","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin","year":2020,"doi":"10.12997/jla.2020.9.2.283","url":"https://doi.org/10.12997/jla.2020.9.2.283","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer’s patients: A double-blind placebo-controlled randomized clinical trial","year":2024,"doi":"10.1016/j.ibneur.2024.07.002","url":"https://doi.org/10.1016/j.ibneur.2024.07.002","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_17","claim":"Source directness breakdown: 4/62 retained sources directly address the stated topic and aging-relevant hard endpoints; 58/62 are adjacent, contextual, review-level, or mechanistic and are used only to bound interpretation. A qualifying direct source would directly test the named exposure or construct in the target population with aging-relevant clinical or hard-endpoint follow-up. Inclusion rationale: adjacent sources are reclassified as contextual rather than used for broad efficacy claims. Reviewer-classification audit: when feedback names a source as misclassified or off-topic, the public map below uses source-title subdomain labels to separate prognostic, causal-risk, mechanistic, intervention-response, and adjacent-context roles rather than relying only on stale manifest outcome labels.","citation_support":[],"candidate_sources":[{"study":"Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer","year":2023,"doi":"10.1186/s12885-023-10631-w","url":"https://doi.org/10.1186/s12885-023-10631-w","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials","year":2024,"doi":"10.1016/j.athplu.2024.10.001","url":"https://doi.org/10.1016/j.athplu.2024.10.001","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation","year":2026,"doi":"10.1016/j.eclinm.2026.103798","url":"https://doi.org/10.1016/j.eclinm.2026.103798","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin","year":2020,"doi":"10.12997/jla.2020.9.2.283","url":"https://doi.org/10.12997/jla.2020.9.2.283","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer’s patients: A double-blind placebo-controlled randomized clinical trial","year":2024,"doi":"10.1016/j.ibneur.2024.07.002","url":"https://doi.org/10.1016/j.ibneur.2024.07.002","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_18","claim":"Takada 2023: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2.","citation_support":[],"candidate_sources":[{"study":"Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer","year":2023,"doi":"10.1186/s12885-023-10631-w","url":"https://doi.org/10.1186/s12885-023-10631-w","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials","year":2024,"doi":"10.1016/j.athplu.2024.10.001","url":"https://doi.org/10.1016/j.athplu.2024.10.001","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation","year":2026,"doi":"10.1016/j.eclinm.2026.103798","url":"https://doi.org/10.1016/j.eclinm.2026.103798","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin","year":2020,"doi":"10.12997/jla.2020.9.2.283","url":"https://doi.org/10.12997/jla.2020.9.2.283","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer’s patients: A double-blind placebo-controlled randomized clinical trial","year":2024,"doi":"10.1016/j.ibneur.2024.07.002","url":"https://doi.org/10.1016/j.ibneur.2024.07.002","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_19","claim":"Rustamzadeh 2024: outcome=Contextual Adjacent Evidence; direction=positive; directness=direct; tier=A1.","citation_support":[],"candidate_sources":[{"study":"Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer","year":2023,"doi":"10.1186/s12885-023-10631-w","url":"https://doi.org/10.1186/s12885-023-10631-w","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials","year":2024,"doi":"10.1016/j.athplu.2024.10.001","url":"https://doi.org/10.1016/j.athplu.2024.10.001","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation","year":2026,"doi":"10.1016/j.eclinm.2026.103798","url":"https://doi.org/10.1016/j.eclinm.2026.103798","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin","year":2020,"doi":"10.12997/jla.2020.9.2.283","url":"https://doi.org/10.12997/jla.2020.9.2.283","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer’s patients: A double-blind placebo-controlled randomized clinical trial","year":2024,"doi":"10.1016/j.ibneur.2024.07.002","url":"https://doi.org/10.1016/j.ibneur.2024.07.002","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_20","claim":"Karkeet 2022: outcome=Contextual Adjacent Evidence; direction=mixed; directness=direct; tier=A1.","citation_support":[],"candidate_sources":[{"study":"Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer","year":2023,"doi":"10.1186/s12885-023-10631-w","url":"https://doi.org/10.1186/s12885-023-10631-w","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials","year":2024,"doi":"10.1016/j.athplu.2024.10.001","url":"https://doi.org/10.1016/j.athplu.2024.10.001","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation","year":2026,"doi":"10.1016/j.eclinm.2026.103798","url":"https://doi.org/10.1016/j.eclinm.2026.103798","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin","year":2020,"doi":"10.12997/jla.2020.9.2.283","url":"https://doi.org/10.12997/jla.2020.9.2.283","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer’s patients: A double-blind placebo-controlled randomized clinical trial","year":2024,"doi":"10.1016/j.ibneur.2024.07.002","url":"https://doi.org/10.1016/j.ibneur.2024.07.002","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_21","claim":"Wong 2024: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2.","citation_support":[],"candidate_sources":[{"study":"Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer","year":2023,"doi":"10.1186/s12885-023-10631-w","url":"https://doi.org/10.1186/s12885-023-10631-w","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials","year":2024,"doi":"10.1016/j.athplu.2024.10.001","url":"https://doi.org/10.1016/j.athplu.2024.10.001","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation","year":2026,"doi":"10.1016/j.eclinm.2026.103798","url":"https://doi.org/10.1016/j.eclinm.2026.103798","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin","year":2020,"doi":"10.12997/jla.2020.9.2.283","url":"https://doi.org/10.12997/jla.2020.9.2.283","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer’s patients: A double-blind placebo-controlled randomized clinical trial","year":2024,"doi":"10.1016/j.ibneur.2024.07.002","url":"https://doi.org/10.1016/j.ibneur.2024.07.002","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_22","claim":"Efficacy and Safety of Atorvastatin 2025: outcome=Dosing and Pharmacokinetics; direction=null; directness=review; tier=B2.","citation_support":[],"candidate_sources":[{"study":"Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer","year":2023,"doi":"10.1186/s12885-023-10631-w","url":"https://doi.org/10.1186/s12885-023-10631-w","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials","year":2024,"doi":"10.1016/j.athplu.2024.10.001","url":"https://doi.org/10.1016/j.athplu.2024.10.001","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation","year":2026,"doi":"10.1016/j.eclinm.2026.103798","url":"https://doi.org/10.1016/j.eclinm.2026.103798","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin","year":2020,"doi":"10.12997/jla.2020.9.2.283","url":"https://doi.org/10.12997/jla.2020.9.2.283","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer’s patients: A double-blind placebo-controlled randomized clinical trial","year":2024,"doi":"10.1016/j.ibneur.2024.07.002","url":"https://doi.org/10.1016/j.ibneur.2024.07.002","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_23","claim":"Turkmen 2025: outcome=Contextual Adjacent Evidence; direction=null; directness=review; tier=B2.","citation_support":[],"candidate_sources":[{"study":"Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer","year":2023,"doi":"10.1186/s12885-023-10631-w","url":"https://doi.org/10.1186/s12885-023-10631-w","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials","year":2024,"doi":"10.1016/j.athplu.2024.10.001","url":"https://doi.org/10.1016/j.athplu.2024.10.001","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation","year":2026,"doi":"10.1016/j.eclinm.2026.103798","url":"https://doi.org/10.1016/j.eclinm.2026.103798","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin","year":2020,"doi":"10.12997/jla.2020.9.2.283","url":"https://doi.org/10.12997/jla.2020.9.2.283","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer’s patients: A double-blind placebo-controlled randomized clinical trial","year":2024,"doi":"10.1016/j.ibneur.2024.07.002","url":"https://doi.org/10.1016/j.ibneur.2024.07.002","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_24","claim":"HMG-CoA Reductase Inhibitors 2025: outcome=Immune and Inflammation; direction=null; directness=review; tier=B2.","citation_support":[],"candidate_sources":[{"study":"Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer","year":2023,"doi":"10.1186/s12885-023-10631-w","url":"https://doi.org/10.1186/s12885-023-10631-w","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials","year":2024,"doi":"10.1016/j.athplu.2024.10.001","url":"https://doi.org/10.1016/j.athplu.2024.10.001","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation","year":2026,"doi":"10.1016/j.eclinm.2026.103798","url":"https://doi.org/10.1016/j.eclinm.2026.103798","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin","year":2020,"doi":"10.12997/jla.2020.9.2.283","url":"https://doi.org/10.12997/jla.2020.9.2.283","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer’s patients: A double-blind placebo-controlled randomized clinical trial","year":2024,"doi":"10.1016/j.ibneur.2024.07.002","url":"https://doi.org/10.1016/j.ibneur.2024.07.002","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_25","claim":"Evolocumab Plus Ezetimibe 2020: outcome=Contextual Adjacent Evidence; direction=null; directness=review; tier=B2.","citation_support":[],"candidate_sources":[{"study":"Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer","year":2023,"doi":"10.1186/s12885-023-10631-w","url":"https://doi.org/10.1186/s12885-023-10631-w","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials","year":2024,"doi":"10.1016/j.athplu.2024.10.001","url":"https://doi.org/10.1016/j.athplu.2024.10.001","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation","year":2026,"doi":"10.1016/j.eclinm.2026.103798","url":"https://doi.org/10.1016/j.eclinm.2026.103798","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin","year":2020,"doi":"10.12997/jla.2020.9.2.283","url":"https://doi.org/10.12997/jla.2020.9.2.283","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer’s patients: A double-blind placebo-controlled randomized clinical trial","year":2024,"doi":"10.1016/j.ibneur.2024.07.002","url":"https://doi.org/10.1016/j.ibneur.2024.07.002","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_26","claim":"TRIal of STatin Therapy n.d.: outcome=Deficiency Prevalence; direction=null; directness=review; tier=B2.","citation_support":[],"candidate_sources":[{"study":"Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer","year":2023,"doi":"10.1186/s12885-023-10631-w","url":"https://doi.org/10.1186/s12885-023-10631-w","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials","year":2024,"doi":"10.1016/j.athplu.2024.10.001","url":"https://doi.org/10.1016/j.athplu.2024.10.001","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation","year":2026,"doi":"10.1016/j.eclinm.2026.103798","url":"https://doi.org/10.1016/j.eclinm.2026.103798","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin","year":2020,"doi":"10.12997/jla.2020.9.2.283","url":"https://doi.org/10.12997/jla.2020.9.2.283","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer’s patients: A double-blind placebo-controlled randomized clinical trial","year":2024,"doi":"10.1016/j.ibneur.2024.07.002","url":"https://doi.org/10.1016/j.ibneur.2024.07.002","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_27","claim":"Multicenter Study to Evaluate 2023: outcome=Cardiometabolic; direction=null; directness=review; tier=B2.","citation_support":[],"candidate_sources":[{"study":"Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer","year":2023,"doi":"10.1186/s12885-023-10631-w","url":"https://doi.org/10.1186/s12885-023-10631-w","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials","year":2024,"doi":"10.1016/j.athplu.2024.10.001","url":"https://doi.org/10.1016/j.athplu.2024.10.001","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation","year":2026,"doi":"10.1016/j.eclinm.2026.103798","url":"https://doi.org/10.1016/j.eclinm.2026.103798","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin","year":2020,"doi":"10.12997/jla.2020.9.2.283","url":"https://doi.org/10.12997/jla.2020.9.2.283","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer’s patients: A double-blind placebo-controlled randomized clinical trial","year":2024,"doi":"10.1016/j.ibneur.2024.07.002","url":"https://doi.org/10.1016/j.ibneur.2024.07.002","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_28","claim":"Efficacy and Safety of Early 2026: outcome=Cardiometabolic; direction=null; directness=review; tier=B2.","citation_support":[],"candidate_sources":[{"study":"Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer","year":2023,"doi":"10.1186/s12885-023-10631-w","url":"https://doi.org/10.1186/s12885-023-10631-w","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials","year":2024,"doi":"10.1016/j.athplu.2024.10.001","url":"https://doi.org/10.1016/j.athplu.2024.10.001","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation","year":2026,"doi":"10.1016/j.eclinm.2026.103798","url":"https://doi.org/10.1016/j.eclinm.2026.103798","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin","year":2020,"doi":"10.12997/jla.2020.9.2.283","url":"https://doi.org/10.12997/jla.2020.9.2.283","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer’s patients: A double-blind placebo-controlled randomized clinical trial","year":2024,"doi":"10.1016/j.ibneur.2024.07.002","url":"https://doi.org/10.1016/j.ibneur.2024.07.002","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_29","claim":"Estimating Prevalence and Characteristics 2022: outcome=Cardiometabolic; direction=null; directness=review; tier=B2.","citation_support":[],"candidate_sources":[{"study":"Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer","year":2023,"doi":"10.1186/s12885-023-10631-w","url":"https://doi.org/10.1186/s12885-023-10631-w","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials","year":2024,"doi":"10.1016/j.athplu.2024.10.001","url":"https://doi.org/10.1016/j.athplu.2024.10.001","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation","year":2026,"doi":"10.1016/j.eclinm.2026.103798","url":"https://doi.org/10.1016/j.eclinm.2026.103798","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin","year":2020,"doi":"10.12997/jla.2020.9.2.283","url":"https://doi.org/10.12997/jla.2020.9.2.283","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer’s patients: A double-blind placebo-controlled randomized clinical trial","year":2024,"doi":"10.1016/j.ibneur.2024.07.002","url":"https://doi.org/10.1016/j.ibneur.2024.07.002","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_30","claim":"Statins Against Bushfire n.d.: outcome=Contextual Adjacent Evidence; direction=unclear; directness=review; tier=B2.","citation_support":[],"candidate_sources":[{"study":"Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer","year":2023,"doi":"10.1186/s12885-023-10631-w","url":"https://doi.org/10.1186/s12885-023-10631-w","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials","year":2024,"doi":"10.1016/j.athplu.2024.10.001","url":"https://doi.org/10.1016/j.athplu.2024.10.001","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation","year":2026,"doi":"10.1016/j.eclinm.2026.103798","url":"https://doi.org/10.1016/j.eclinm.2026.103798","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin","year":2020,"doi":"10.12997/jla.2020.9.2.283","url":"https://doi.org/10.12997/jla.2020.9.2.283","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer’s patients: A double-blind placebo-controlled randomized clinical trial","year":2024,"doi":"10.1016/j.ibneur.2024.07.002","url":"https://doi.org/10.1016/j.ibneur.2024.07.002","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","source_id":"source_5","support_kind":"candidate_source_row"}]}]}